

Background

- Scalable ways to identify patients for cancer genetic testing are needed.
- We developed & clinically validated a brief patient-administered digital tool which performs guideline-based assessments of the need for cancer genetic counseling & testing.
- Ongoing evaluation of such digital tools is important for ensuring their accuracy and for informing tool improvements.

Aim

Assess the frequency, nature, and cause of differences in assessments made by a digital tool and the GC who subsequently saw the patient.


Methods

Retrospective chart review of patients who completed the digital tool and subsequently saw a GC. Data extracted:

- ☰ Tool's and GC's assessments
- 📍 Personal & family history of cancer
- 📄 Which aspects of history met criteria

A senior cancer GC (AD) investigated the cause of differences in assessment between the digital tool and the GC.

Hereditary cancer risk assessment digital tool accurately assesses whether patients meet testing criteria, with some assessments changing at the GC visit, often due to changes in family history.



Comparisons of assessments by a hereditary cancer risk assessment digital tool and genetic counselors confirm accuracy of tool and suggest ways to improve it

Ashley Daley, Andi Hila, Kiley Johnson, Colleen Caleshu



Results

📅 October 2021 - November 2022

181 Patients
41y Mean age

12% Had a personal history of cancer (22/181)


Reasons for Differences

0% No differences were due to tool inaccurately assessing provided history (0/181)

1% Very recent change to guidelines (2/181)

7% History entered in the tool changed at visit (13/181)

Most changes in reported history involved changes to a key detail of family history (85% (11/13)):



Improving the Digital Tool

Two patients entered endometrial cancer in the tool for a relative who had cervical cancer; one said this was because cervical cancer was not an option in the tool. To improve user experience and accuracy of history, tool is being updated to include cervical cancer as an option.